Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04500587




Registration number
NCT04500587
Ethics application status
Date submitted
30/07/2020
Date registered
5/08/2020

Titles & IDs
Public title
Phase 1 First in Human Study of ZN-d5 as a Single Agent
Scientific title
Phase 1 First in Human Dose-Escalation Study of ZN-d5 as a Single Agent in Subjects With Non-Hodgkin Lymphoma or Acute Myeloid Leukemia
Secondary ID [1] 0 0
ZN-d5-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Myeloid Leukemia 0 0
Non Hodgkin Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ZN-d5

Experimental: ZN-d5 Single Agent Dose Escalation - NHL - Non-Hodgkin Lymphoma

Experimental: ZN-d5 Single Agent Dose Escalation - AML - Acute Myeloid Leukemia


Treatment: Drugs: ZN-d5
Oral agent; 25 mg or 100 mg formulation
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Observed Dose Limiting Toxicities
Timepoint [1] 0 0
Through completion of Cycle 1; 1 to 2 months.
Primary outcome [2] 0 0
Incidence and severity of AEs, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, v 5.0
Timepoint [2] 0 0
Through study completion, typically < 12 months
Secondary outcome [1] 0 0
Pharmacokinetic parameters for ZN-d5 - Cmax
Timepoint [1] 0 0
approximately 6 months
Secondary outcome [2] 0 0
Pharmacokinetic parameters for ZN-d5 - Tmax
Timepoint [2] 0 0
approximately 6 months
Secondary outcome [3] 0 0
Pharmacokinetic parameters for ZN-d5 - AUC
Timepoint [3] 0 0
approximately 6 months
Secondary outcome [4] 0 0
For NHL, evaluate response according to the Lugano 2014 classification
Timepoint [4] 0 0
Through study completion, typically < 12 months
Secondary outcome [5] 0 0
For AML, remission rate based on European LeukemiaNet 2017 criteria
Timepoint [5] 0 0
Through study completion, typically < 12 months
Secondary outcome [6] 0 0
For AML, duration of remission based on European LeukemiaNet 2017 criteria
Timepoint [6] 0 0
Through study completion, typically < 12 months

Eligibility
Key inclusion criteria
Key

NHL: relapsed or refractory NHL including DLBCL, FL, MZL, MCL, LCL, LPL and PTC

* Subjects must have received at least 2 prior lines of therapy and have either failed or not be eligible for any available therapies expected to provide clinical benefit and have measurable disease.

AML: Primary, secondary, or treatment-related AML, relapsed or refractory to prior therapy, which may include failure of one cycle of induction therapy.

* White blood cell count < 25 × 109/L. Cytoreduction prior to treatment is acceptable.
* Subjects may not be pregnant and must agree to use an effective method of contraception.
* Eastern Cooperative Oncology Group performance status = 2.
* Estimated life expectancy of at least 12 weeks.
* Adequate hematologic and organ function, including creatinine clearance = 60 mL/min.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Recent interventions including major surgery, radiation therapy, stem cell transplant.
* Treatment with anti-neoplastic agents with 5 half-lives.
* Significant unresolved toxicity from prior treatments including active GVHD.
* Active central nervous system disease.
* Clinically substantial myocardial impairment.
* Prior therapy with venetoclax.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/10/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2025
Actual
Sample size
Target
115
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,TAS
Recruitment hospital [1] 0 0
Site 2708 - Darlinghurst
Recruitment hospital [2] 0 0
Site 2704 - Liverpool
Recruitment hospital [3] 0 0
Site 2710 - Kurralta Park
Recruitment hospital [4] 0 0
Site 2709 - Hobart
Recruitment postcode(s) [1] 0 0
- Darlinghurst
Recruitment postcode(s) [2] 0 0
- Liverpool
Recruitment postcode(s) [3] 0 0
- Kurralta Park
Recruitment postcode(s) [4] 0 0
- Hobart
Recruitment outside Australia
Country [1] 0 0
Bulgaria
State/province [1] 0 0
Sofia
Country [2] 0 0
Bulgaria
State/province [2] 0 0
Varna
Country [3] 0 0
Croatia
State/province [3] 0 0
Zagreb
Country [4] 0 0
Korea, Republic of
State/province [4] 0 0
Pusan
Country [5] 0 0
Korea, Republic of
State/province [5] 0 0
Seoul
Country [6] 0 0
Poland
State/province [6] 0 0
Gdansk
Country [7] 0 0
Spain
State/province [7] 0 0
Barcelona
Country [8] 0 0
Spain
State/province [8] 0 0
Bilbao
Country [9] 0 0
Spain
State/province [9] 0 0
Valencia
Country [10] 0 0
Ukraine
State/province [10] 0 0
Kiev

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
K-Group Alpha Inc. /a subsidiary of Zentalis Pharmaceuticals
Address 0 0
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
K-Group Alpha Inc. /a subsidiary of Zentalis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04500587